Zenotech Laboratories (BOM:532039) Interest Expense : ₹0.0 Mil (TTM As of Mar. 2025)

View and export this data going back to 1996. Start your Free Trial

What is Zenotech Laboratories Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Zenotech Laboratories's interest expense for the three months ended in Mar. 2025 was ₹ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was ₹0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Zenotech Laboratories's Operating Income for the three months ended in Mar. 2025 was ₹ 27.4 Mil. Zenotech Laboratories's Interest Expense for the three months ended in Mar. 2025 was ₹ 0.0 Mil. Zenotech Laboratories has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Zenotech Laboratories Interest Expense Historical Data

The historical data trend for Zenotech Laboratories's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenotech Laboratories Interest Expense Chart

Zenotech Laboratories Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Interest Expense

Get a 7-Day Free Trial

-15.48

-12.15

-1.12

-9.45

Zenotech Laboratories Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Zenotech Laboratories Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

Zenotech Laboratories (BOM:532039) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zenotech Laboratories's Interest Expense for the three months ended in Mar. 2025 was ₹0.0 Mil. Its Operating Income for the three months ended in Mar. 2025 was ₹27.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was ₹0.0 Mil.

Zenotech Laboratories's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Zenotech Laboratories had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Zenotech Laboratories Ltd has no debt.

Zenotech Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zenotech Laboratories Ltd (BOM:532039) » Definitions » Interest Expense

Traded in Other Exchanges

N/A

Address

Survey No. 250-252, Turkapally Village, Shamirpet Mandal, RR District, Hyderabad, TG, IND, 500 078

Website

http://zenotechlab.com

Zenotech Laboratories Ltd is an India-based pharmaceutical company. It is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio primarily serves niche therapy areas like oncology and anesthesiology. It also manufactures products such as granulocyte-colony stimulating factor (GCSF) and Granulocyte-macrophage colony-stimulating factor (GMCSF). The company earns a vast majority of the revenue from the sale of its contract research and manufacturing services.

Zenotech Laboratories Headlines

No Headlines